Jawad Maha S, Shah Chirag, Wilkinson J Ben, Wallace Michelle, Mitchell Christina K, Wobb Jessica, Gustafson Gregory S, Brabbins Donald S, Grills Inga S, Chen Peter Y
*Department of Radiation Oncology, Oakland University William Beaumont School of Medicine, Royal Oak, MI †Department of Radiation Oncology, Summa Cancer Institute, Summa Health System, Akron, OH ‡Department of Radiation Oncology, Willis-Knighton Health System/LSU Health Science Center, Shreveport, LA.
Am J Clin Oncol. 2017 Oct;40(5):483-489. doi: 10.1097/COC.0000000000000190.
Limited long-term data exist regarding outcomes for patients treated with accelerated partial breast irradiation (APBI), particularly, when stratified by American Society for Radiation Oncology (ASTRO) Consensus Statement (CS) risk groups. The purpose of this analysis is to present 5- and 7-year outcomes following APBI based on CS groupings.
A total of 690 patients with early-stage breast cancer underwent APBI from 1993 to 2012, receiving interstitial brachytherapy (n=195), balloon-based brachytherapy (n=290), or 3-dimensional conformal radiotherapy (n=205) at a single institution. Patients were stratified into suitable, cautionary, and unsuitable groups with 5-year outcomes analyzed. Seven-year outcomes were analyzed for a subset with follow-up of ≥2 years (n=625).
Median follow-up was 6.7 years (range, 0.1 to 20.1 y). Patients assigned to cautionary and unsuitable categories were more likely to have high-grade tumors (21% to 25% vs. 9%, P=0.001), receive chemotherapy (15% to 38% vs. 6%, P<0.001), and have close/positive margins (9% to 11% vs. 0%, P<0.001). There was no difference in ipsilateral breast tumor recurrence at 5 or 7 years: 2.2%, 1.2%, 2.8% at 5 years (P=0.57), and 2.2%, 1.9%, 4.6% at 7 years (P=0.58) in the suitable, cautionary, and unsuitable groups, respectively. As compared with the suitable group, increased rates of distant metastases were noted for the unsuitable and cautionary groups at 5 years (P=0.04).
No differences in rates of ipsilateral breast tumor recurrence were seen at 5 or 7 years when stratified by ASTRO CS groupings. Modest increases in distant recurrence were noted in the cautionary and unsuitable groups. These findings suggest that the ASTRO CS groupings stratify more for systemic recurrence and may not appropriately select patients for whole versus partial breast irradiation.
关于接受加速部分乳腺照射(APBI)治疗的患者的长期数据有限,尤其是按美国放射肿瘤学会(ASTRO)共识声明(CS)风险组分层时。本分析的目的是呈现基于CS分组的APBI治疗后的5年和7年结果。
1993年至2012年,共有690例早期乳腺癌患者在单一机构接受了APBI治疗,其中195例接受组织间近距离放疗,290例接受球囊近距离放疗,205例接受三维适形放疗。患者被分为合适、谨慎和不合适组,并分析了5年结果。对随访时间≥2年的子集(n = 625)分析了7年结果。
中位随访时间为6.7年(范围0.1至20.1年)。被归类为谨慎和不合适类别的患者更有可能患有高级别肿瘤(21%至25%对9%,P = 0.001),接受化疗(15%至38%对6%,P < 0.001),且切缘接近/阳性(9%至11%对0%,P < 0.001)。5年或7年时同侧乳腺肿瘤复发率无差异:合适、谨慎和不合适组在5年时分别为2.2%、1.2%、2.8%(P = 0.57),在7年时分别为2.2%、1.9%、4.6%(P = 0.58)。与合适组相比,不合适组和谨慎组在5年时远处转移率增加(P = 0.04)。
按ASTRO CS分组分层时,5年或7年同侧乳腺肿瘤复发率无差异。谨慎和不合适组远处复发有适度增加。这些发现表明,ASTRO CS分组更多地是对全身复发进行分层,可能无法适当地选择全乳照射与部分乳腺照射的患者。